Ivosidenib monotherapy in IDH1 mutated myelodysplastic neoplasm/syndrome
- 25 August 2026
- journal article
- research article
- Published by Springer Nature in Leukemia
- p. 1-10
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AMLHemaSphere, 2025
- Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemiaCell Stem Cell, 2025
- Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trialThe Lancet Haematology, 2023
- Myelodysplastic Syndrome associated TET2 mutations affect NK cell function and genome methylationNature Communications, 2023
- Molecular International Prognostic Scoring System for Myelodysplastic SyndromesNEJM Evidence, 2022
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic NeoplasmsLeukemia, 2022
- Clonal selection confers distinct evolutionary trajectories in BRAF-driven cancersNature Communications, 2019
- Durable Remissions with Ivosidenib in IDH1 -Mutated Relapsed or Refractory AMLNew England Journal of Medicine, 2018
- The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-HydroxyglutarateCancer Cell, 2010
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyThe Lancet Oncology, 2009